Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

Summary

This is open-label, phase II study enrolling advanced BTC patients who have failed to 1st-line chemotherapy.

Timeline

Start

2020-11-01

Primary completion

2023-07-31

Completion

2024-12-31

Publications

• Yoon J, Lee CK, Kim JW, Kang B, Park SJ, Kim JW, Chon HJ, Choi HJ, Lee MA, Kim TY, Oh DY. Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer. J Hepatol. 2026 Apr;84(4):766-775. doi: 10.1016/j.jhep.2025.10.032. Epub 2025 Nov 24.

Drugs

Indications